Paratek Pharmaceuticals (PRTK) Lowered to Strong Sell at ValuEngine
ValuEngine downgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a strong sell rating in a research note published on Friday.
Other equities research analysts have also recently issued reports about the stock. Robert W. Baird reaffirmed a buy rating and issued a $40.00 price objective on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. Guggenheim initiated coverage on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They issued a buy rating and a $44.00 price objective on the stock. Cantor Fitzgerald set a $50.00 price objective on shares of Paratek Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, October 17th. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, November 1st. Finally, BidaskClub cut shares of Paratek Pharmaceuticals from a sell rating to a strong sell rating in a research report on Saturday, December 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Paratek Pharmaceuticals has a consensus rating of Buy and an average target price of $40.00.
Paratek Pharmaceuticals (PRTK) traded down $0.25 on Friday, reaching $17.90. 253,304 shares of the company traded hands, compared to its average volume of 368,769. The company has a market cap of $507.13, a PE ratio of -4.80 and a beta of 0.70. Paratek Pharmaceuticals has a 1-year low of $13.95 and a 1-year high of $29.00. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.